Frequency and functional translation of low muscle mass in overweight and obese patients with COPD

Felipe V. C. Machado¹,²,³,⁴*, Martijn A. Spruit¹,²,³, Miriam T. J. Groenen¹, Sarah Houben-Wilke¹, Paula P. van Melick¹, Nidia A. Hernandes⁴, Annemie M. W. J. Schols²,³, Fabio Pitta⁴, Emiel F. M. Wouters¹,³,⁵ and Frits M. E. Franssen¹,²,³

Abstract

Background: Cut offs for fat-free mass index (FFMI) and appendicular skeletal muscle mass index (ASMI) are available for diagnosing low muscle mass in patients with COPD. This study aimed to investigate: (1) the frequency of low muscle mass (FFMI and ASMI) applying different cut-offs and (2) the functional translation (clinical impact) of low muscle mass, in patients with COPD stratified into BMI categories.

Methods: Patients with COPD were assessed regarding body composition, exercise capacity, quadriceps muscle strength, symptoms of anxiety and depression, dyspnea and quality of life upon referral to pulmonary rehabilitation. The proportion of patients with low muscle mass was compared among BMI categories. Clinical outcomes between patients with normal and low muscle mass within each BMI category were compared.

Results: 469 patients with COPD were included for analyses. The frequency of patients classified as low FFMI varied significantly according to the choice of cut-off (32 to 54%; P < 0.05), whereas the frequency of patients with low ASMI was 62%. When applying age-gender-BMI-specific cut-offs, 254 patients (54%) were classified as low FFMI. The choice of the cut-off affected the frequency of patients with low muscle mass in all BMI categories. Overweight and obese patients with low muscle mass were more frequently males and presented worse pulmonary function, exercise capacity and muscle strength compared with overweight and obese patients with normal muscle mass.

Conclusions: Approximately half of the overweight and obese patients with COPD have low muscle mass when applying age-gender-BMI-specific cut-offs. Low muscle mass is associated with worse functional outcomes in overweight and obese COPD patients.

Keywords: Prevalence, Sarcopenia, Obesity, Exercise tolerance, Quality of life

Introduction

Chronic obstructive pulmonary disease (COPD) is defined by the presence of chronic respiratory symptoms and airflow limitation [1]. Extra-pulmonary features and comorbidities contribute to the burden of this disease [2] and are recognized as treatable traits in the integrated management of the disease [3]. Low fat-free mass (FFM), as a whole-body marker of muscle mass, is commonly found in COPD [4, 5] and strongly associated with muscle weakness [6, 7], exercise intolerance [8] and poor health status [9]. Obesity is another condition frequently coinciding with COPD [10] related to increased...
respiratory symptoms [11], reduced health status [12] and low functional performance [13].

For the measurement of body composition in COPD, one of the most appropriate methods is dual-energy X-ray absorptiometry (DEXA), which allows a combined assessment of FFM, fat-mass and bone mineral density [14]. In addition, DEXA provides an assessment of FFM and fat-mass at regional level and can provide the measurement of appendicular skeletal muscle mass index (ASMI), which is used to define sarcopenia according to fixed cut-offs < 7.23 kg·m$^{-2}$ for men and < 5.67 kg·m$^{-2}$ for women [15]. However, DEXA is relatively expensive and not widely available. As an alternative, bioelectrical impedance analysis (BIA) is an easy, non-invasive and relatively less expensive method to assess whole-body FFM, widely used in many clinical settings [16, 17]. Despite not enabling assessment of ASMI, BIA can provide an estimate of the whole-body FFM that is usually normal- ized for body size (dividing FFM for height squared) and expressed as FFM index (FFMI). Irrespective of the methodology of assessment, the European Respiratory Society statement on nutritional management of COPD, proposed a cut-off of 17 kg·m$^{-2}$ for males and 15 kg·m$^{-2}$ for females to identify patients with low FFMI [14]. These values correspond to the 10th percentile of most normal to underweight patients with COPD [14]. However, it is important to consider that body composition is positively related to body mass index (BMI) and that FFMI declines with aging [18, 19]. Hence, the use of fixed cut-off values may result in underdiagnoses of low FFMI in overweight or obese patients [20, 21] and overdiagnoses in underweight patients and those with advanced age. For underweight (BMI lower than 18.5 kg·m$^{-2}$) patients with COPD, the clinical impact of the choice of the cut-off value might be less relevant, since low BMI by itself, provides useful prognostic information [22]; however, this issue is relevant in COPD patients with BMI corresponding to normal weight, overweight and obesity, since BMI is not reliable to determine (ab)normal fat mass and FFM values in these groups [23, 24].

In 2014, Franssen et al. [25] published age-sex-BMI-specific reference values for FFMI based on a sample of 186,975 healthy subjects. The frequency of low FFMI in overweight and obese patients with COPD diagnosed according to age-sex-BMI-specific cut-offs in comparison with fixed cut-off for FFMI and ASMI is currently unknown, as well as whether and to what extent low FFMI is translated in functional impairment in patients in different BMI categories. We hypothesize that the use of age-sex-BMI-specific cut-offs may improve the diagnosis of body composition abnormalities in patients with higher BMI and discriminate groups of patients with more impairment in physical function and clinical characteristics within the category of high BMI patients. Therefore, the aims of the present study were to investigate: (1) the frequency of low muscle mass (FFMI and ASMI) applying different cut-offs and (2) the functional translation (clinical impact) of low muscle mass, in patients with COPD stratified into BMI categories.

Material and methods

Study population

The current analysis used data from the Chance Study: an observational, prospective, single-center study focused on COPD, health status and comorbidities [26]. The study was approved by the Medical Ethical Committee of the Maastricht University Medical Centre + (METC 11-3-070) and is registered at http://www.trialregister.nl (NTR 3416). Inclusion criteria were: (1) diagnosis of COPD according to GOLD strategy [1], (2) referral for a comprehensive pulmonary rehabilitation program at CIRO (Horn, the Netherlands) and (3) no exacerbation at least 4 weeks prior to the study. Patients were excluded if they had a history of other lung diseases, had undergone lung surgery or had malignancy within the last five years and/or presented BMI lower than 18.5 kg·m$^{-2}$. All patients gave written informed consent, and the study was carried out in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Procedures

In addition to medical history, anthropometric and demographic variables, DEXA (Lunar Expert-XL Bone Densitometer; Lunar Radiation Corporation, Madison, WI, USA) was performed to assess body composition. FFMI was calculated by dividing FFM (lean mass plus bone mineral content (BMC) by height$^2$. ASMI was calculated as the sum of lean mass (minus BMC) for each of the four extremities divided by height$^2$. The following measurements were also performed: symptoms of dyspnoea using the modified Medical Research Council (mMRC) dyspnoea scale; exercise capacity using a symptom-limited cardiopulmonary incremental cycle test, the six-minute walking test (6MWT) and a constant work rate exercise test (CWRT); quadriceps peak muscle strength using a isokinetic dynamometer (Biodex System 4 Pro, Biodex Medical Systems, Inc., New York, USA); health related quality of life (HRQL) using St. George’s Respiratory Questionnaire (SGRQ); and symptoms of anxiety and depression using Hospital Anxiety and Depression Scale (HADS).

Statistical analysis

Patients were classified into BMI categories according to World Health Organization criteria [27]: normal weight
(18.5–24.9 kg·m⁻²), overweight (25–29.9 kg·m⁻²) or obese (≥ 30 kg·m⁻²). Afterwards, patients were sub-classified within each BMI category into low or normal FFMI and low or normal ASMI. For FFMI, two cut-offs were applied: the European Respiratory Society statement sex-specific values [14] (17 kg·m⁻² for males and 15 kg·m⁻² for females) and the 10th percentiles of the reference values from the UK Biobank general population (age-sex-BMI-specific cut-offs) [25]. For ASMI classification, the cut-offs applied (<7.23 kg·m⁻² for men; <5.67 kg·m⁻² for women) were in accordance with the Health Aging and Body Composition (Health ABC) Study [15].

Continuous variables are presented as mean and standard deviation (SD) or median [interquartile range 25–75%], according to normality in data distribution. Categorical variables are presented as absolute and relative frequency. A chi-square test of independence was conducted to investigate whether there is association between the choice of different cut-offs and the proportion of patients diagnosed with low FFMI and ASMI. The comparisons of continuous variables between patients with normal or low FFMI and normal or low ASMI within each BMI category were performed with Student’s t-test for independent samples or Mann–Whitney U-test, whereas the comparisons of categorical variables were performed with a Chi-square test. Statistics were performed using SPSS (version 24.0, IBM Corporation, Armonk, NY, USA). A priori, the level of significance was set at P < 0.05.

Results
The Chance study enrolled 518 patients with COPD. Nineteen patients were excluded from the analysis because of missing body composition analysis and 30 patients were excluded due to BMI < 18.5 kg·m⁻². The general characteristics of the included patients are presented in Table 1. Patients were on average 64 years and presented severe airflow limitation, reduced exercise capacity and quadriceps muscle strength and impaired HRQL. More than half of patients were overweight or obese.

Frequency of low FFMI
Figure 1 shows the frequency of low FFMI according to the different cut-offs. The overall frequency of patients classified as low FFMI was lower when applying the fixed cut-off in comparison with the age-sex-BMI-specific cut-off (32% and 54%, respectively; P < 0.05).

Considering the fixed cut-off, the frequency of low FFMI decreased with an increase in BMI; the frequency of patients with low FFMI in normal weight, overweight and obese categories was 58%, 17% and 1%, respectively. Considering the age-sex-BMI-specific cut-offs, the frequency of patients with low FFMI, in normal weight, overweight and obese groups was 57%, 58% and 42%, respectively. The frequency of low FFMI as identified by the fixed cut-off was comparable to the frequency identified by the age-sex-BMI-specific cut-off for patients with a normal weight BMI, but lower for patients with an overweight or obese BMI (P < 0.05, for all) (Fig. 1).

Clinical impact of low FFMI
Table 1 presents the comparisons of outcomes between patients with normal and low FFMI, according to the age-sex-BMI specific cut-offs, after stratification into BMI categories. A higher frequency of males with low FFMI were found in patients with an overweight or obese BMI. In patients with normal weight, those with low FFMI presented lower forced expiratory volume in the first second (FEV₁), transfer factor for carbon monoxide (TLCO), six-minute walking distance (6MWD), peak load during cycle ergometry (Wmax), peak oxygen consumption during cycle ergometry (VO₂max), quadriceps peak torque (PT) and hip bone mineral density (BMD) compared with normal weight patients with normal FFMI. Overweight patients with low FFMI presented lower FEV₁, Wmax and PT, compared with overweight patients with normal FFMI. Finally, obese patients with low FFMI presented lower TLCO, VO₂max and PT compared to patients with normal FFMI from the same BMI category.

Frequency of low ASMI
The overall frequency of patients classified as low ASMI was 62% (Fig. 1). The frequency of patients with low ASMI in normal weight, overweight and obese groups was 88%, 60% and 16%, respectively. The frequency of low ASMI was significantly higher than the frequency of low FFMI (according to the age-sex-BMI adjusted cut-offs) in normal weight patients, comparable in overweight patients, and lower for patients stratified into the obese category (P < 0.05, for all) (Fig. 1).

Clinical impact of low ASMI
Comparisons of outcomes between patients with normal and low ASMI after stratification into BMI categories are presented in Table 2. In patients with normal weight, those with low ASMI presented lower FEV₁, TLCO, 6MWD, Wmax, VO₂max, CWRT, quadriceps PT, lumbar BMD, and a higher proportion of this group were males and patients with symptoms of dyspnea (mMRC ≥ 2) (P < 0.05, for all). Considering the overweight patients, those with low ASMI presented lower FEV₁, 6MWD, Wmax, VO₂max, quadriceps PT. For the group of obese patients, those with low ASMI presented lower FEV₁, TLCO, 6MWD, Wmax, VO₂max, quadriceps PT, and higher symptoms of dyspnea.
Discussion
This study compared the frequency of abnormal body composition diagnosed according to fixed whole-body (FFMI) and regional (ASMI) cut-offs versus age-sex-BMI-specific cut-offs for FFMI in patients with COPD, after stratification into BMI categories. The study has three main findings. First, low FFMI is more commonly diagnosed in overweight and obese patients with COPD using age-sex-BMI-specific cut-offs, in contrast to when fixed cut-offs are applied. Second, the effects of low FFMI are less pronounced in higher categories of BMI, but patients with low FFMI in overweight/obese categories are characterized by worse lung function, muscle strength and exercise tolerance compared to patients with comparable BMI and normal FFMI. Finally, the frequency of males with low FFMI in overweight/obese was higher, despite the use of a sex-specific cut-off, suggesting that sex-dependent FFMI disturbances in these groups of patients.

The first study to apply age-sex-BMI-specific cut-offs for FFMI [23] found that patients with COPD were 3 times more likely to present sarcopenic obesity compared with a control group and that the presence of sarcopenic obesity was associated with worse physical performance and higher systemic inflammation. Despite identifying participants with relative imbalance in fat and FFMI across a wide range of BMI [23], this study did not compare the frequency of low FFMI and ASMI according to different cut-offs or the impact of presenting low FFMI after stratification into BMI categories. Another study found that the frequency of patients with low FFMI according to a fixed cut-off was 34.5%. However, from the total sample with low FFMI, 36%, 53% and 11% were underweight, normal weight and overweight, respectively, whereas no obese patient presented low FFMI.
Similarly, a previous study which aimed to identify distinct clusters based on the comorbidity profiles in a cohort of moderate to very severe patients with COPD, found that the frequency of low FFMI was 28%, but the metabolic cluster, characterized by a higher frequency of obesity (61%), presented no patients classified as low FFMI (according to fixed cut-offs values) [20]. The study of van de Bool et al. [21] applied the fixed cut-offs for ASMI and found a high frequency of low ASMI across all BMI categories (100%, 97%, 88% and 54% in underweight, normal weight, overweight and obese, respectively). The explanation for the higher frequency of low ASMI in overweight and obese patients in that study compared to the current is unclear as age, sex distribution, disease severity, study center and methodology to assess body composition were comparable.

In addition to further identification of patients with low FFMI, this study also demonstrates the functional translation of low FFMI in patients with higher BMI. We found that the differences in outcomes between overweight/obese patients with normal and low FFMI were less pronounced when compared with the differences observed in normal weight patients, suggesting a lower influence of presenting low FFMI in patients with higher BMI. Our hypothesis is that the direct effects of increased BMI on respiratory mechanics at rest and during exercise could be related with relatively preserved lung function and functional outcomes [28]. In addition, despite FFMI being strongly related with muscle strength, other determinants of strength (e.g., muscle activation, specific force of the muscle fibers) [29] could be enhanced in lower limbs of patients with higher BMI, due to training effect for being constantly submitted to overload during activities of daily living (e.g., walking, climbing stairs). This is supported by findings from the study of van de Bool et al. [21] whose results show that muscle strength increases linearly with an increasing BMI and that patients with low FFMI and abnormally obese (i.e. higher BMI) present higher efficiency of the lower limbs muscles (expressed as the ratio between muscle strength and ASMI).

Exercise and nutrition-based interventions as part of comprehensive pulmonary rehabilitation program should focus not only on treating the deleterious effects of obesity, but also on maintaining or increasing FFM, lower-limb muscle function and exercise tolerance in these patients. In obese patients with COPD, a previous study showed that caloric restriction with maintained protein intake associated with resistance exercise training is effective to promote weight loss, without the loss of muscle mass and with improvement in functional outcomes [30]. These benefits have also been demonstrated in obese older adults, however with additional effects of including aerobic training to caloric restriction and resistance training [31].

In the present study there were no differences in HRQL between patients with normal and low FFMI according to the age-sex-BMI-specific cut-offs. This finding is in contrast with previous studies which showed that patients with low FFMI present worse HRQL, as assessed by using the SGRQ [32, 33]. However, it is not yet clear if the fact of presenting low FFMI is independently associated with reduction of quality of life, since in both studies, other variables, such as dyspnea [32] and exercise capacity [33] were deemed to be mediators of the effect of low FFMI on HRQL. In the present study quality of life was, in general, impaired in patients with COPD, independently of body weight and FFMI categories. Pulmonary rehabilitation is strongly recommended to improve HRQL in patients with COPD and evidence support that patients with low FFMI can improve HRQL to the same extent as patients with normal FFMI [33].

The present study included patients with COPD referred for pulmonary rehabilitation. Therefore, the observed frequency of low FFMI is probably higher compared to the general COPD population. However, rather than establishing the exact frequency of low FFMI in patients with COPD or compare the agreement of different cut-offs, the focus of this study was on the comparison of applying age-sex-BMI-specific and fixed cut-offs to the same cohort of patients for diagnosing low FFMI and ASMI and to provide a better understanding on the effects of low FFMI in different BMI categories. Moreover, in the present study DEXA was used to calculate FFMI, while normative values for FFMI were based on BIA [25]. BIA may lead to a slight underestimation of
Table 2 Characteristics of COPD patients referred for pulmonary rehabilitation with normal and low ASMI, after stratification into BMI categories

| BMI group | Normal weight (n=205) | Overweight (n=156) | Obese (n=103) |
|-----------|-----------------------|--------------------|---------------|
| ASMI group | Normal (n=25) | Low (n=180) | Normal (n=62) | Low (n=94) | Normal (n=87) | Low (n=16) |
| Subjects, % males | 28.0 | 54.4* | 53.2 | 63.8 | 55.1 | 62.0 |
| Age, years | 62 ± 9 | 64 ± 9 | 65 ± 10 | 66 ± 9 | 64 ± 9 | 63 ± 7 |
| BMI, kg m⁻² | 21.9 ± 1.9 | 21.9 ± 1.8 | 27.8 ± 1.5 | 27.0 ± 1.2# | 33.5 ± 2.9 | 31.7 ± 2.1# |
| FFMI, kg m⁻² | 16.3 [15.3–18.0] | 15.3 [14.2–17.0]† | 18.5 [16.5–19.6] | 17.1 [15.7–18.3]# | 20.1 [18.4–21.4] | 18.0 [15.6–19.2]# |
| FEV₁, l | 1.3 (0.91–1.84) | 0.98 [0.74–1.37]† | 1.47 [0.96–2.01] | 1.09 [0.77–1.57]† | 1.49 [1.09–1.83] | 1.01 [0.66–1.60]† |
| FEV₁/FVC, % | 69 [46–96] | 45 [32–65]# | 58 [47–84] | 47 [37–64]# | 57 [44–68]# | 41.3 [27.3–54.5]† |
| VO₂max, ml m⁻¹ min⁻¹ | 45.3 [31.6–52.1]# | 43.4 [32.5–50.7]† | 32.6 [25.5–43.0]† | 44.0 [36.6–52.7] | 33.5 [28.1–41.3]† |
| HADS Depression score, pts | 7 [4–11] | 6 [3–10] | 7 [4–10] | 8 [4–11] | 8 [4–10] | 6 [3–10] |
| HADS Anxiety score, pts | 9 [3–11] | 6 [4–11] | 6 [5–12] | 7 [5–11] | 7 [5–11] | 11 [5–13]† |
| 6MWD, m | 523 ± 92 | 417 ± 123# | 471 ± 110 | 391 ± 122# | 426 ± 114 | 356 ± 97* |
| 6MWD, %pred | 81 ± 12 | 63 ± 18# | 76 ± 15 | 64 ± 17# | 71 ± 16 | 59 ± 15† |
| Wmax, W | 84 ± 61–98 | 55 [44–74]# | 74 [58–100] | 64 [46–78]† | 74 [61–95] | 54 [37–72]† |
| Wmax, %pred | 69 [46–96] | 45 [32–65]# | 58 [48–84] | 47 [37–64]# | 58 [43–86] | 45 [36–55]* |
| VO₂max, ml m⁻³ | 1244 [880–1438] | 888 [691–1034]# | 1156 [900–1402] | 1060 [873–1303] | 1230 [995–1501] | 958 [818–1147]* |
| VO₂max, %pred | 75 [51–102] | 52 [37–72]# | 67 [53–88] | 56 [46–76]† | 67 [53–97] | 55 [46–70] |
| CWRT, s | 285 [219–491] | 206 [154–298]† | 255 [187–360] | 214 [175–314] | 258 [172–461] | 230 [172–304] |
| Quadriceps PT, Nm | 90 ± 20 | 81 ± 29 | 139 ± 35 | 144 ± 29 | 113 ± 42 | 93 ± 29 |
| Quadriceps PT, %pred | 72 ± 18 | 58 ± 15# | 76 ± 16 | 65 ± 17# | 79 ± 18 | 64 ± 13* |
| SGRQ Total score, pts | 55 [38–68] | 63 [49–75] | 58 [46–70] | 65 [52–74] | 65 [52–75] | 66 [61–79] |
| HADS Anxiety score, pts | 9 [3–11] | 6 [4–11] | 6 [5–12] | 7 [5–11] | 7 [5–11] | 11 [5–13]† |
| HADS Depression score, pts | 7 [4–11] | 6 [3–10] | 7 [4–10] | 8 [4–10] | 8 [4–10] | 6 [4–14] |
| ASMI, kg m⁻² | 6.39 ± 0.80 | 5.55 ± 0.79# | 6.93 ± 0.86 | 6.07 ± 0.87# | 7.53 ± 1.00 | 6.20 ± 0.76 |
| Lumbar spine T-score | −2.04 ± 0.60 | −1.05 ± 1.53# | −0.88 ± 1.35 | −0.90 ± 1.67 | −0.74 ± 1.46 | −0.98 ± 1.41 |
| Hip T-score | −1.66 ± 0.99 | −1.75 ± 0.98# | −1.66 ± 0.89 | −1.70 ± 0.98 | −1.11 ± 1.03 | −1.41 ± 0.80 |

Mean ± standard deviation, median [interquartile range 25–75%] or frequency reported. ASMI = appendicular skeletal muscle mass index, BMI = body mass index, FFMI = fat-free mass index, BIA = bioelectric impedance analysis, FEV₁ = forced expiratory volume in the first second, FVC = forced vital capacity, TLCO = transfer factor for carbon monoxide, mMRC = modified Medical Research Council, 6MWD = six-minute walking distance, Wmax = peak work rate during cycle ergometry, VO₂max = peak oxygen uptake during cycle ergometry, CWRT = time constant work rate test, PT = peak torque, SGRQ = St George’s Respiratory Questionnaire, HADS = hospital anxiety and depression questionnaire. *P<0.05 versus normal FFMI from the same BMI group. †P<0.01 versus normal FFMI from the same BMI group. #P<0.001 versus normal FFMI from the same BMI group.

FFM when compared with DEXA in patients with COPD [34]. Although the 10th percentile values for FFMI based on BIA may represent an even lower percentile of FFMI compared with DEXA, this would result in a slightly underestimated proportion of patients with low FFMI and the frequency of low FFMI would be actually higher than presented. In addition, the ERS statement on nutritional management in COPD does not mention or recommend the use of method-specific reference values [14]. Thus, the use of age-sex-BMI-specific reference values has shown potential to improve the diagnosis of body composition abnormalities in patients with higher BMI, mainly in clinical practice, considering that BIA is more commonly available than DEXA.

While this study showed that large proportion of overweight and obese COPD patients suffer from low FFMI and its functional consequences, it is not fully understood whether and to what extent these patients benefit from non-pharmacological treatment. Studying the effects of exercise training in combination with nutritional support in overweight and obese patients with low FFMI is an interesting topic for future investigation. Furthermore, the prognostic value and impact of low FFMI on long-term outcomes in overweight and obese patients should be investigated. Finally, longitudinal changes in body composition in these sub-group of patients with COPD and their impact on outcomes can also be part of future research projects.

Conclusion
This study showed that the application of age-sex-BMI-specific cut-offs resulted in a high proportion of overweight and obese patients with COPD presenting low FFMI and these patients are characterized by worse lung function, muscle strength and exercise tolerance. While it was previously reported that low FFMI is absent in...
overweight and obese patients with COPD, the present study encourages the application of age-sex-BMI-specific cut-offs in order to identify these patients. The results of the present study have important consequences for the assessment of overweight and obese patients with COPD.

Abbreviations
COPD: Chronic obstructive pulmonary disease; FFM: Fat-free mass index; ASMI: Appendicular skeletal muscle mass index; BMI: Body mass index; FFM: Fat-free mass; DEVA: Dual-energy X-ray absorptiometry; BIA: Bioelectrical impedance analysis; BMC: Bone mineral content; mAMRC: Modified Medical Research Council; 6MW: Six-minute walking test; CWR: Constant work rate exercise test; HRQL: Health related quality of life; SGRQ: St. George’s Respiratory Questionnaire; HADS: Hospital Anxiety and Depression Scale; FEV1: Forced expiratory volume in the first second; TLCO: Transfer factor for carbon monoxide; 6MWD: Six-minute walking distance; Wmax: Peak load during cycle ergometry; VO2max: Peak oxygen consumption during cycle ergometry; PT: Peak torque; BMD: Bone mineral density.

Acknowledgements
We are grateful to all patients who were willing to participate in the current study.

Authors’ contributions
The authors’ responsibilities were as follows: FVCM: wrote the paper and contributed to interpretation of the data. MTJG: performed statistical analysis. SHW, PvM, NAH, AMWJS and FP: contributed to interpretation of the data and critical revision of the manuscript. SHW, PvM, NAH, AMWJS and FP: contributed to interpretation of the data. MTJG: performed statistical analysis, contributed to interpretation of the data and critical revision of the manuscript and contributed to the conception and design of the research. All authors approved the manuscript.

Funding
This study was financially supported by Lung Foundation Netherlands (3.4.10.015) and GlaxoSmithKline (SC0115406). FVCM is financially supported by ZonMW (ERACoSysMed grant #R0030355). MAS reports grants from Lung Foundation Netherlands, grants from Stichting Astma Bestrijding, grants and personal fees from Boehinger Ingelheim, grants and personal fees from AstraZeneca, outside the submitted work: FMEF reports grants and personal fees from AstraZeneca, personal fees from Boehinger Ingelheim, personal fees from Chiesi, personal fees from GlaxoSmithKline, grants and personal fees from Novartis, personal fees from TEVA, outside the submitted work.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The current analysis used data from the Chance Study which was approved by the Medical Ethical Committee of the Maastricht University Medical Centre + (METC 11-3-070). The present study was approved by the board of directors of CIRO (Horn, the Netherlands). All patients gave written informed consent and the study was carried out in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Research and Development, CIRO+; Centre of Expertise for Chronic Organ Failure, 6080 AB Haelen, Hornerheide 1, Postbus 4009, 6085 NM Horn, The Netherlands. 2 NUTRIM-School of Nutrition and Translational Research in Metabolism, Maastricht, The Netherlands. 3 Department of Respiratory Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands. 4 Laboratory of Research in Respiratory Physiotherapy, Department of Physical Therapy, State University of Londrina, Londrina, Brazil. 5 Ludwig Boltzmann Institute for Lung Health, Vienna, Austria.

Received: 13 November 2020   Accepted: 22 March 2021
Published online: 25 March 2021

References
1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2020. https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMF.pdf Accessed Apr 2020.
2. Agusti A, Soriano JB. COPD as a systemic disease. COPD. 2008;5(2):133–48.
3. Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47(2):410–9.
4. Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr. 2005;82(1):53–9.
5. Vestbo J, Prescott E, Almdal T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen city heart study. Am J Respir Crit Care Med. 2006;173(1):79–83.
6. Franssen FM, Broekhuizen R, Janssen PP, Wouters EFM, Schols AMWJ. Limb muscle dysfunction in COPD: effects of muscle wasting and exercise training. Med Sci Sports Exerc. 2005;37(1):2–9.
7. Seymour JM, Spruit MA, Hopkinson NS, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J. 2010;36(1):81–8.
8. Baarends EM, Schols AM, Mostert R, Wouters EF. Peak exercise response in relation to tissue depletion in patients with chronic obstructive pulmonary disease. Eur Respir J. 1997;10(12):2807–13.
9. Mostert R, Gosis A, Weling-Scheepers C, Wouters EF, Schols AM. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. Respir Med. 2000;94(9):859–67.
10. Vanfleteren LE, Lamprecht B, Studnicka M, et al. Body mass index and chronic airflow limitation in a worldwide population-based study. Chron Respir Dis. 2016;13(2):90–101.
11. Sin DD, Jones RL, Man SF. Obesity is a risk factor for dyspnea but not for airflow obstruction. Arch Intern Med. 2002;162(13):1477–81.
12. Cecere LM, Littman AJ, Slatore CG, et al. Obesity and COPD: associated symptoms, health-related quality of life, and medication use. COPD. 2011;8(4):275–84.
13. Ramachandran K, McCusker C, Connors M, Zuwallack R, Lahiri B. The influence of obesity on pulmonary rehabilitation outcomes in patients with COPD. Chron Respir Dis. 2008;5(4):205–9.
14. Schols AM, Ferreira IM, Franssen FM, Gosker HR, Janssens W, Muscaritoli M, Pison C, Mølken MR, Slinde F, Steiner MC, et al. Nutritional assessment and therapy in COPD. A European Respiratory Society statement. Eur Respir J. 2014;44(4):1304–20.
15. Newman AB, Kupelian V, Visser M, et al. sarcopenia: alternative definitions and associations with lower extremity function. J Am Geriatr Soc. 2003;51(11):1602–9.
16. Kyle Ug, Bosaeus I, De Lorenzo AD, et al. Bioelectrical impedance analysis—part I: review of principles and methods. Clin Nutr. 2004;23(5):1226–43.
17. Kyle Ug, Bosaeus I, De Lorenzo AD, et al. Bioelectrical impedance analysis—part II: utilization in clinical practice. Clin Nutr. 2004;23(6):1430–53.
18. Kyle Ug, Schultz Y, Dupertuis YM, Pichard C. Body composition interpretation. Contributions of the fat-free mass index and the body fat mass index. Nutrition. 2003;19(7–8):597–604.
19. Bosy-Westphal A, Müller MJ. Identification of skeletal muscle mass depletion across age and BMI groups in health and disease—there is need for a unified definition. Int J Obes (Lond). 2015;39(3):379–86.
20. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation
in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728–35.

21. Van De Boel C, Rutten EPA, Franssen FME, Wouters EFM, Schols AMWJ. Antagonistic implications of sarcopenia and abdominal obesity on physical performance in COPD. Eur Respir J. 2015;46(2):336–45.

22. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–12.

23. Joppa P, Tkacova R, Franssen FME, et al. Sarcopenic obesity, functional outcomes, and systemic inflammation in patients with chronic obstructive pulmonary disease. J Am Med Dir Assoc. 2016;17(8):712–8.

24. Machado FVC, Schneider LP, Fonseca J, et al. Clinical impact of body composition phenotypes in patients with COPD: a retrospective analysis. Eur J Clin Nutr. 2019;73(11):1512–9.

25. Franssen FME, Rutten EPA, Groenen MTJ, Vanfleteren LE, Wouters EFM, Spruit MA. New reference values for body composition by bioelectrical impedance analysis in the general population: results from the UK Biobank. J Am Med Dir Assoc. 2014;15(6):1–6.

26. Smid DE, Wilke S, Jones PW, et al. Impact of cardiovascular comorbidities on COPD Assessment Test (CAT) and its responsiveness to pulmonary rehabilitation in patients with moderate to very severe COPD: protocol of the Chance study. BMJ Open. 2015;5(7):e007536.

27. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;1–253.

28. Ora J, Laveneziana P, Wadell K, Preston M, Webb KA, O’Donnell DE. Effect of obesity on respiratory mechanics during rest and exercise in COPD. J Appl Physiol. 2011;111(1):10–9.

29. Maltais F, Decramer M, Casaburi R, et al. An official American thoracic society/European respiratory society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;189(9):15–62.

30. McDonald VM, Gibson PG, Scott HA, et al. Should we treat obesity in COPD? The effects of diet and resistance exercise training. Respirology. 2016;21(5):875–82.

31. Villareal DT, Aguirre L, Gurney AB, et al. Aerobic or resistance exercise, or both, in dieting obese older adults. N Engl J Med. 2017;376(20):1943–55.

32. Shoup R, Dalsky G, Warner S, et al. Body composition and health-related quality of life in patients with obstructive airways disease. Eur Respir J. 1997;10(7):1576–80.

33. Berton DC, Silveira L, da Costa CC, De Souza RM, Winter CD, Teixeira PJZ. Effectiveness of pulmonary rehabilitation in exercise capacity and quality of life in chronic obstructive pulmonary disease patients with and without global fat-free mass depletion. Arch Phys Med Rehabil. 2013;94(8):1607–14.

34. Steiner MC, Barton RL, Singh SJ, Morgan MOL. Bedside methods versus dual energy X-ray absorptiometry for body composition measurement in COPD. Eur Respir J. 2002;19(4):626–31.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.